Johnson & Johnson’s $1.03 Billion Volume Ranks 91st as Shares Climb 1.54% Amid Legal and Regulatory Challenges

On September 11, 2025, , ranking 91st in terms of trading activity across the market. , reflecting renewed investor interest in the healthcare sector amid mixed broader market conditions.

Recent developments highlight regulatory and operational challenges for the company. A U.S. District Court in New Jersey denied a motion to dismiss a lawsuit alleging JNJ’s opioid distribution practices contributed to the national addiction crisis. While the ruling stops short of a final verdict, it underscores prolonged legal exposure that could impact future earnings. Additionally, the FDA has extended its review of JNJ’s novel oncology drug Jemperli, citing the need for further data on long-term patient outcomes.

Strategic shifts in the company’s portfolio also drew attention. JNJ announced the divestiture of its consumer health business to Kenvue Inc. , signaling a focus on high-margin pharmaceuticals and medical devices. Analysts noted the transaction could streamline R&D spending but may reduce near-term revenue diversification. Concurrently, the company expanded its partnership with Vertex Pharmaceuticals to co-develop gene therapies for rare diseases, a move expected to bolster long-term growth prospects.

To run this back-test accurately, we need to nail down a few practical details. If you’d like, I can assume sensible defaults and proceed automatically, but first please review the key items below: Universe—“Top 500 by trading volume” can be drawn from many stock universes. Default suggestion: all common stocks listed on NYSE & NASDAQ. Execution prices—Typical overnight strategy buys at the day’s close and exits at next day’s close. Position sizing—Default: equal-weight across the 500 names. Frictional costs—Default: ignore commissions/slippage. Benchmark—SPY total return or something else for relative comparison. If these defaults are acceptable, just say “run with defaults,” or tell me the specific changes you’d like.